Dr. Lindsay Rosenwald – Know More About Lindsay Rosenwald

Several of Dr. Rosenwald’s other companies in which he founded have became headline makers because of the treatment advances they have made. Among those companies are Sypress Biosciences with their Savella, useful in the treatment of fibromyalgia and another breakthrough from the same company is the Prosorba Column, used to treat severe rheumatoid arthritis. Other advancements from other companies in Dr. Lindsay Rosenwald’s portfolio include Trisinox developed by Polarx, it is used in acute leukemia cases; Peramivir, a vaccine for H1N1 influenza that has worldwide approval for treatment , it is from Biocryst Pharmaceuticals; and there is Titan Pharmaceuticals with its Fanapt for schizophrenia treatment ; other companies in the portfolio have developed anti-obesity drug that is breakthroughs the biggest obesity treatment breakthrough in the past thirty years and other achievements. These advancements are so important because of the seriousness of the ailments that these drugs and devices are used for. many people have found great benefit from them and had relief of their suffering.

Dr. Lindsay Rosenwald is not only known for his founding of these breakthrough biotechnology companies, but for his giving to make possible even more breakthroughs. He is a very active philanthropist distributing his giving among many venues. His Rosenwald Foundation helps by donating to institutions that educate and do research in the biotechnology and pharmaceutical fields.

Dr. Rosenwald is the current director of several other companies both privately owned and public. These include Neose Technologies Inc., Interneuron Pharmaceuticals Inc., and Keryx Inc. In addition to these roles he also holds  positions as a member of the board of directors for the Jewish Republican Coalition as well as having a seat on the Columbia-Presbyterian Health Sciences Advisory Council.  The Jewish Republican Coalition aims to connect the Jewish population in America with the Republican officeholders so that there will be a greater understanding and working together between them. His advisory seat enables Dr. Rosenwald to help Columbia University College of Physicians and Surgeons with his input in important decisions. Dr. Rosenwald is able to partake in very influential and important issues concerning peoples health and welfare by the many ways he gives to society.

Lindsay Rosenwald started his professional research at Pennsylvania State University in 1973 after graduating from Abington High School. He excelled an enterprise and was particularly intrigued with economics and finance.

In quest for his lifelong dream, Rosenwald entered Temple University’s University of Medicine. After graduating from Temple University in 1983, he began an internship at Abington Hospital before starting his own private practice. After filling out his internship, he worked as a health-care professional in his very own practice for 2.5 years. Even though he cherished being a medical doctor, Rosenwald preferred a career where he could blend his two loves – medical science and business enterprise.

Rosenwald quit his private practice in 1986 to go to Wall Street where he took on a position as a Physician / Analyst, an extremely exclusive position with just a few people doing it at that time. Despite the belief that doctors don’t make good investors, Dr Rosenwald excelled at this position. He had a passion for improving investment finance open to the health care sector and that is primarily why he worked there. People admired him and respected his opinions and knowledge. Even though he missed treating individuals, he recognized this was exactly where he belonged. During this time, he also worked for DH Blair and Company, a private investment organization, as the managing director of corporate finance. Over time, he left D.H. Blair and Company to pay attention to a new venture and firm.

Over time, he has broadened this company by starting new companies and attaining control of other biotech companies. The organization has financed more than two dozen companies within the last three years. He creates these companies by concentrating on the growth of both the corporate and biotechnology portions. All of these firms are separate entities, but interact to support one another. The firms that Rosenwald handles have licensed or acquired over a hundred experimental stage drugs.

One of the most notable accomplishments for Lindsay Rosenwald is setting the record for the speediest acceptance of a new drug to market. In merely thirty months, Arsenic Trioxide was created and approved by the FDA for the treatment of a deadly form of leukemia. This drug has been in the marketplace around the world for over ten years and has saved and prolonged 1000s of lives.

Rosenwald has created really groundbreaking companies one of his companies sold to J&J for more than One Billion Dollars even though they only had 1 drug with phase 2 data. He has also founded the very first publicly traded stem cell company, gene therapy company, and cancer vaccine company. As Rosenwald as the leader, his firms have created probably the most valuable and groundbreaking drug treatments of the 21st century. To add to his achievements he comes up with the very first successful medicine to aid those who are obese.

One of the reasons that Rosenwald’s companies have been profitable is that he hires PhDs, MDs, MBAs, and other experts to serve as his senior level professionals. These people usually have experience in business, however they also tend to possess vast knowledge in the medical community. They are driven to produce new drugs as soon as possible. Some of these medicines have the possibility to change the way we look at medical care entirely today. He has also created the Rosenwald Foundation that has contributed millions of dollars to health care and science instruction to help create the future of medicine.

Lindsay Rosenwald has built his business by constantly looking towards the future and now is no different. He speculates that over the next 20 years the biotech industry will continue to enlarge exponentially. Rosenwald predicts that major biotech breakthroughs of the future will come from smaller, startup biotech companies instead of the massive biotech firms we see these days. He feels the two most pressing problems we face today are heart disease and cancer.

Lindsay Rosenwald was always been in limelight with his achievements. He has made the news many times over the years due to the direction and vision of owner and founder Lindsay Rosenwald. The following are some of the highlights of these media mentions.

Money Central is MSN’s online resource for all things financial. Whether you’re looking for information about taxes, investments, or how to manage your personal finances, this is a great resource to reference. In a 2003 article by Michael Bush, Lindsay Rosenwald was listed the number one corporate investor.  Praised for his investments in biotech companies such as Cell Therapeutics and Neose Technologies which have led to up to 280% gains in the course of six months, he is named the “top all-star” of corporate insiders.

The New York Times is one of the most famous newspapers in all the US. Even over twenty years ago, they recognized the business intellect of Dr. Lindsay Rosenwald. The article details Rosenwald’s collegiate background and how he excelled in economics and finance, yet pursued his lifelong dream of being a doctor. After a few years of private medical practice, he has combined these two areas of expertise to discovering and investing in breaking edge medical and biotech companies, defying the stereotype that doctors cannot be good investors.

Temple Times is the school news letter of Lindsay Rosenwald’s alma mater, Temple University in Philadelphia. Naming Rosenwald as the “specialist to see if your hedge fund is ailing”, it focuses in on his business success as an entrepreneur that started as a doctor. As the founder and owner, the business has expanded to have offices on three different continents.